




## DASHBOARD VIEW



- 1 **REBATE BREAKDOWN**  
Whether for APP or a brand tier program, the dashboard summarizes your level attained and your rebate.
- 2 **TOTAL SAVINGS SYNOPSIS**  
The dashboard offers a quick overview of this year's savings to-date for APP and the brand tier programs, as well as the total value of free goods earned.
- 3 **BRAND TIER LEVELS**  
Click to easily view your brand tier program's savings by brand.



## APP VIEW




- 4 **GRAPH MARKERS**  
Color coded markers show current year-to-date points and previous year-to-date comparison.
- 5 **GRAPH LEGEND**  
The new graphics displaying your year performance are intuitively color-coded by year so you know exactly where you stand.
- 6 **FULL YEAR GRAPH**  
Displays your full year performance for 2015 and compares it to your full year performance in 2014.
- 7 **PROGRAM STANDINGS**  
Want to know where you stand in the program? Compare your points against the APP level assignments and your rank versus other APP participants in the leaderboard.



- 8 **GROWTH REWARD TRACKER**  
See what rebate level you are tracking towards with the new Growth Tracker feature.

## BRANDS VIEW



9 BOTOX COSMETIC (onabotulinumtoxinA)  
View your Botox Cosmetic points and growth year-to-date versus the same time frame a year ago.

10 KYBELLA (deoxycholic acid) injection  
Welcome the addition of Kybella to the brands page and view a graph showing your Kybella points progress for 2016.

11 BRAND TABS  
Effortlessly jump between viewing your achievements in the different brand tier programs using the new tab interface for Juvederm XC, Juvederm Voluma XC, Natrelle, Latisse (bimatoprost ophthalmic solution 0.03%), and SkinMedica.

12 2016 BRAND TIER PROGRAM GRAPH  
View your status and year-to-date performance accross all brands and compare them to your year ago performances for the same time frame.

13 2015 BRAND TIER PROGRAM GRAPH  
See your full year performance in 2015 contrasted with your full year performance in 2014.

### BOTOX® Cosmetic (onabotulinumtoxinA) Important Information

#### Indications

##### Glabellar Lines

BOTOX® Cosmetic (onabotulinumtoxinA) for injection is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

##### Lateral Canthal Lines

BOTOX® Cosmetic is indicated for the temporary improvement in the appearance of moderate to severe lateral canthal lines associated with orbicularis oculi activity in adult patients.

**IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING**

**WARNING: DISTANT SPREAD OF TOXIN EFFECT**

Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses, including spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and upper limb spasticity and at lower doses.

**CONTRAINDICATIONS**

BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

**WARNINGS AND PRECAUTIONS**

**Lack of Interchangeability between Botulinum Toxin Products**

The potency Units of BOTOX® Cosmetic are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of BOTOX® Cosmetic cannot be compared to nor converted into units of any other botulinum toxin products assessed with any other specific assay method.

**Spread of Toxin Effect**

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines) have been reported.

**Serious Adverse Reactions With Unapproved Use**

Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX® injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX® to the site of injection and/or adjacent structures. In several of the cases, patients had pre-existing dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX®. The safety and effectiveness of BOTOX® for unapproved uses have not been established.

**Hypersensitivity Reactions**

Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such reactions occur, further injection of BOTOX® Cosmetic should be discontinued and appropriate medical therapy immediately instituted. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot be reliably determined.

**Cardiovascular System**

There have been reports following administration of BOTOX® of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including pre-existing cardiovascular disease. Use caution when administering to patients with pre-existing cardiovascular disease.

**Pre-existing Neuromuscular Disorders**

Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, dysphagia, and respiratory compromise from onabotulinumtoxinA (see Warnings and Precautions).

**Dysphagia and Breathing Difficulties**

Treatment with BOTOX® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing (see Boxed Warning).

**Pre-existing Conditions at the Injection Site**

Caution should be used when BOTOX® Cosmetic treatment is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s).

**Human Albumin and Transmission of Viral Diseases**

This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) also is considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin.

**ADVERSE REACTIONS**

The most frequently reported adverse event following injection of BOTOX® Cosmetic for glabellar lines was eyelid ptosis (3%).

The most frequently reported adverse event following injection of BOTOX® Cosmetic for lateral canthal lines was eyelid edema (1%).

**DRUG INTERACTIONS**

Co-administration of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of BOTOX® Cosmetic may potentiate systemic anticholinergic effects.

The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX® Cosmetic.

**USE IN SPECIFIC POPULATIONS**

BOTOX® Cosmetic is not recommended for use in children or pregnant women. It is not known whether BOTOX® Cosmetic is excreted in human milk. Caution should be exercised when BOTOX® Cosmetic is administered to a nursing woman.

For more information on BOTOX® Cosmetic, please see the accompanying full Prescribing Information including Boxed Warning and Medication Guide.

Please see BOTOX® Cosmetic Full Prescribing Information including Boxed Warning and Medication Guide.